Claims for Patent: 9,364,493

Summary for Patent: 9,364,493

Title:	Methods and compositions for enhancing the uptake of therapeutic agents by target cells
Abstract:	The present invention relates to a new use of a known medicament. Specifically, the invention relates to methods and compositions for enhancing the therapeutic efficacy of a therapeutic agent by increasing the uptake of the therapeutic agent by target cells, and in particular relates to a pharmaceutical composition comprising a regulating agent of lipid raft/caveolae-dependent endocytic pathway and some therapeutic agents, such as anti-tumor agents. The invention also relates to a method for screening a regulating agent of lipid raft/caveolae-dependent endocytic pathway capable of enhancing the therapeutic efficacy of anti-tumor agents.
Inventor(s):	Luo; Yongzhang (Beijing, CN), Chen; Yang (Beijing, CN), Fu; Yan (Beijing, CN), Jia; Lin (Beijing, CN), Chang; Guodong (Beijing, CN)
Assignee:	Tsinghua University (Beijing, CN) Beijing Protgen LTD. (Beijing, CN)
Application Number:	14/008,428
Patent Claims:	1. A method of increasing the uptake of a therapeutic agent by a target cell in a subject comprising administering to a subject in need thereof (i) a therapeutic agent and (ii) an inhibitor of lipid raft/caveolae-dependent endocytic pathway, wherein the therapeutic agent is selected from the group consisting of (i) a naturally occurring endostatin or a derivative thereof, (ii) a recombinant human endostatin or a derivative thereof and (iii) an antibody against epidermal growth factor receptor (EGFR), wherein the inhibitor of the lipid raft/caveolae-dependent endocytic pathway is Nystatin and wherein the subject is suffering from a tumor. 2. The method of claim 1, wherein the endostatin comprises an amino acid sequence as shown in SEQ ID NO.1 or SEQ ID NO.2. 3. The method of claim 1, wherein the endostatin has the amino acid sequence as shown in SEQ ID NO.3 or SEQ ID NO.4. 4. The method of claim 1, wherein the endostatin derivative is a polyethylene glycol (PEG) modified endostatin. 5. The method of claim 4, wherein the polyethylene glycol (PEG) is monomethoxy PEG with an average molecular weight of 5-40 kD. 6. The method of claim 5, wherein the PEG is monomethoxy PEG propionaldehyde. 7. The method of claim 6, wherein the average molecular weight of the monomethoxy PEG propionaldehyde is 20 kD. 8. The method of claim 4, wherein the endostatin is modified by polyethylene glycol (PEG) at the site of its N-terminal .alpha.-amine. 9. The method of claim 1, wherein the antibody is a monoclonal antibody against epidermal growth factor receptor (EGFR). 10. The method of claim 9, wherein the monoclonal antibody against epidermal growth factor receptor (EGFR) is Cetuximab. 11. The method of claim 1, wherein the tumor is selected from the group consisting of lung cancer, pancreatic cancer, liver cancer, stomach cancer, colorectal cancer, esophagus cancer, nasopharyngeal carcinoma, malignant melanoma, bone cancer, lymphoma, breast cancer, cervical cancer, prostate cancer, hemangioma, Neuroendocrine tumor, oral cancer, sarcoma, renal cancer and gall bladder cancer. 12. The method of claim 1, wherein the inhibitor of lipid raft/caveolae-dependent endocytic pathway is administered via a parenteral route selected from the group consisting of intravenous injection, intravenous infusion, hypodermic injection, intramuscular injection, intraperitoneal injection, subcutaneous-embed, transdermal absorption, and hepatic arterial injection. 13. The method of claim 12, wherein the inhibitor of lipid raft/caveolae-dependent endocytic pathway is prepared in the form of liposome encapsulation. 14. A pharmaceutical composition comprising: (a) a therapeutic agent which is endostatin or an antibody against epidermal growth factor receptor (EGFR) and (b) an inhibitor of lipid raft/caveolae-dependent endocytic pathway which is Nystatin.

Details for Patent 9,364,493

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2031-03-28
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2031-03-28